



13th Vaccine Congress

15–18 September 2019 • Bangkok, Thailand



Programme

Sunday 15 September 2019

17:00-18:30 Registration and Welcome Drinks Reception

Monday 16 September 2019

08:15-09:15	Researcher Academy– ECR Session Fundamentals of Manuscript Preparation <i>Room: Moon/Lunar</i>	Researcher Academy -Mid Career Session Research Collaborations <i>Room: Galaxy 2</i>
09:30-11:00	OPENING PLENARY SESSION <i>Chairs: Greg Poland and Kiat Ruxrungtham</i> <i>Room: Moon/Lunar</i>	
09:30-09:40	Opening remarks Conference Chair and Local Chair, Gregory A. Poland and Kiat Ruxrungtham	
09:40-10:20	KEY01 - Winner of the Schneerson-Robbins Prize Reducing Pneumonia Morbidity and Mortality; The Potential for New Respiratory Vaccines Kathryn M. Edwards, Director, Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, USA	
10:20-11:00	KEY02 – Winner of the 2019 Edward Jenner Lifetime Achievement and VACCINE Prize Vaccines, a renewed opportunity for our society Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline Vaccines, USA	
11:00-11:30	Refreshment break <i>Room: Galaxy</i>	
11:30-13:00	BREAKOUT SESSION 1 Vaccines against Emerging Diseases (Ebola/Zika/Dengue/Chik) <i>Chairs: Tony Fooks and Nopporn Sittisombut</i> <i>Room: Moon</i>	BREAKOUT SESSION 2 Vaccine Safety and Hesitancy <i>Chairs: Steve Jacobsen and Punnee Pitisuttithum</i> <i>Room: Lunar</i>
11:30-12:00	INV01 Continued Progress in the Development of a Single-Dose VLP-Based Chikungunya Vaccine Sean Bennett, Emergent Biosolutions, USA	INV02 Sequential design and analysis considerations when using electronic health care data to rapidly quantify new vaccine safety evidence Jennifer Nelson Kaiser Permanente, USA
12:00-12:15	O1.1 Development of a Plasmid-Launched Live-Attenuated Vaccine (PLLAV) platform to generate novel multi-valent vaccines against viral pathogens L. Sanchez-Felipe, KU Leuven, Belgium	O2.1 A brief review of adversomics: understanding genetic drivers for adverse events after vaccination I. Ovsyannikova, Mayo Clinic and Foundation, USA
12:15-12:30	O1.2 Development of thermostable multivalent filovirus vaccines based on recombinant insect-cell expressed subunits A.T. Lehrer, University of Hawaii at Manoa, USA	O2.2 Rotavirus vaccination in France: a benefit risk analysis accounting for indirect protection S. Escolano, Inserm, France
12:30-12:45	O1.3 Developing a novel, safe and effective platform for generating flavivirus vaccines A. Auguste, Virginia Polytechnic Institute and State University, USA	O2.3 Revisiting vaccine hesitancy on twitter: from exploratory research to public health policy C. Eisenhauer, Institut Pasteur, France
12:45-13:00	O1.4 A universal dengue vaccine induces protection in nonhuman primates and mice mediated by T cells: a step towards ADE prevention A. Reyes-Sandoval, University of Oxford, UK	O2.4 Uptake of recommended vaccines in pregnancy P. Van Buynder, Griffith University, Australia
13:00-14:00	Lunch <i>Room: Galaxy</i>	

14:00-15:30	BREAKOUT SESSION 3 Vaccines against influenza <i>Chairs: Florian Krammer and Alita Kongchanagul</i> <i>Room: Moon</i>	BREAKOUT SESSION 4 Vaccines against tropical and neglected diseases <i>Chairs: Tony Fooks and Kanitha Patarakul</i> <i>Room: Lunar</i>
14:00-14:30	INV03 Challenges in developing seasonal and pandemic influenza vaccines Kanta Subbarao , <i>WHO Melbourne, Australia</i>	INV04 Molecular determinants of the clinical and epidemiological fitness of dengue virus Eng Eong Ooi , <i>Duke-NUS Medical School, Singapore</i>
14:30-14:45	O3.1 Chicken IFITM knockout technology for increased vaccine production M. Fife , <i>The Pirbright Institute, UK</i>	O4.1 Vaccines targeting sexual development of malaria parasites in the mosquito vector- a step towards malaria elimination N. Kumar , <i>George Washington University, USA</i>
14:45-15:00	O3.2 Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination B. Combadiere , <i>CIMI – Paris (U1135), France</i>	O4.2 A Randomized Open-Label Trial of 2-Dose or 3-Dose Pre-Exposure Rabies Prophylaxis Among Thai Children P. Janewongwirot , <i>Chulalongkorn University, Thailand</i>
15:00-15:15	O3.3 Safety, immunogenicity, and batch consistency of a Quadrivalent inactivated influenza vaccine In Indonesian Population M. Dhamayanti , <i>Universitas Padjadjaran, Indonesia</i>	O4.3 Recombinant BCG expressing <i>Mycobacterium ulcerans</i> antigens imparts enhanced protection against experimental Buruli ulcer S. Lee , <i>Duke University, USA</i>
15:15-15:30	O3.4 The assessment of outer membrane vesicles derived from Escherichia coli Nissle 1917 as a novel mucosal adjuvant in intranasal inactivated influenza vaccine. K Saito , <i>National Institute of Infectious Diseases, Japan</i>	O4.4 Immunogenicity of virus-like particle (VLP)-based coronavirus vaccines J-E. Park , <i>College of Veterinary Medicine, Chungnam National University, Republic of Korea</i>
15:30-16:00	Refreshment break <i>Room: Galaxy</i>	
	BREAKOUT SESSION 5 Vaccine Adjuvants <i>Chairs: Danny Altmann and Alain Jacquet</i> <i>Room: Moon</i>	BREAKOUT SESSION 6 RSV and other childhood vaccines <i>Chairs: Thanyawee Puthanakit and Niranjn Bhat</i> <i>Room: Lunar</i>
16:00-16:30	INV05 Immune Potentiators and Vaccine Adjuvants – Limiting Inflammation and Improving Responses Aaron Esser-Kahn , <i>University of Chicago, USA</i>	INV06 Vaccines against RSV: Two Steps Forward, One Step Back Niranjn Bhat , <i>Center for Vaccine Innovation and Access PATH, USA</i>
16:30-16:45	O5.1 Small molecule inhibitor of TBK1 as adjuvant for the Plasmid-Launched Live-Attenuated Vaccine against the yellow fever virus S. Sharma , <i>Rega Instituut, Belgium</i>	O6.1 Optimized recombinant Newcastle disease virus expressing the F protein of respiratory syncytial virus has improved antigen expression levels and immunogenicity N. Mena , <i>Icahn School of Medicine at Mount Sinai, USA</i>
16:45-17:00	O5.2 Withdrawn	O6.2 Genetic vaccination against RSV using non-human papilloma viruses L. Bayer , <i>Fraunhofer Institute for Cell Therapy and Immunology, Germany</i>
17:00-17:15	O5.3 Immunological mechanism of synergistic anti-cancer activities by activation of TLR9 and STING B. Temizoz , <i>The University of Tokyo (IMSUT), Japan</i>	O6.3 Determinants of maternal pertussis vaccination acceptability among pregnant and non-pregnant women in the Netherlands C. Anraad , <i>Maastricht University, The Netherlands</i>
17:15-17:30	O5.4 Identification of immunostimulatory domains of flagellin for better adjuvant design T-D. Doan , <i>National Pingtung University of Science and Technology, Taiwan, China.</i>	O6.4 A randomized-controlled trial with different doses of a recombinant acellular pertussis vaccine in women of childbearing age (WOCBA) T. Puthanakit , <i>Chulalongkorn University, Thailand</i>
17:30-19:00	Drinks Reception, Poster Session 1 and Professional picture opportunity <i>Take a moment to have your picture taken by a professional photographer</i> <i>Room: Galaxy</i>	
19:00-19:30	Editorial Panel Discussion 1 (interactive sessions involving Vaccine Journal Editors)	

	<i>Room: Moon</i>	
Tuesday 17 September 2019		
08:00-09:00	Researcher Academy – Early Career Resarcher Session Fundamentals of Peer Review <i>Room: Moon/Lunar</i>	Researcher Academy -Mid Career Session Research Data Management <i>Room: Galaxy 2</i>
09:00-11:00	PLENARY SESSION 2 Vaccine Hesitancy <i>Chairs: Ken Ishii and Terapong Tantawichien</i> <i>Room: Moon/Lunar</i>	
09:00-09.20	KEY03 Addressing Vaccine Hesitancy: How can industry, government stakeholders and the public health community work together to improve confidence in vaccination? Imraan Munshi, MSD, USA	
09:20-09.40	KEY04 Challenge Against Vaccine Hesitancy - Knowledge among Health Care Workers is the Key Hajime Kamiya, National Institute of Infectious Disease (NIID), Japan	
09:40-10:00	KEY05 Vaccine Wars: A Call for Civility and A Way Forward Greg Poland, Editor in Chief, Vaccine and Mayo Clinic, USA	
10:00-10:15	ST1 Impact of 'No Jab' policies on parents and immunisation service in a large tertiary hospital in Melbourne, Australia Raffaella Armiento, Royal Children's Hospital, Australia	
10:15-10:30	ST2 Are adjuvants dangerous? Wet and dry science minimizing vaccine hesitancy Ken Ishii, University of Tokyo, Japan	
10:30-11:00	Panel Discussion	
11:00-11:30	Refreshment break <i>Room: Galaxy</i>	
	BREAKOUT SESSION 7 Vaccines against Emerging Diseases (Ebola/Zika/Dengue/Chik) <i>Chairs: Usa Thisyakorn and Rick Kennedy</i> <i>Room: Moon</i>	BREAKOUT 8 Hepatitis A/B/C vaccines <i>Chairs: Yong Poovorawan and Inna Ovsyannikova</i> <i>Room: Lunar</i>
11:30-12:00	INV07 Dengue Vaccine: A Key for Prevention Usa Thisyakorn, Tropical Medicine, Chulalongkorn University, Thailand	INV08 Elimination of hepatitis by the year 2030; role of hepatitis vaccines Yong Poovorawan, Chulalongkorn University, Thailand
12:00-12:15	O7.1 Pre-clinical protective efficacy of a virus-like particle-based vaccine against Zika virus R. Tandavanitj, MRC-University of Glasgow Centre for Virus Research, UK	O8.1 Control of hepatitis A through routine vaccination: experience of the Tyva Republic A. Saryglar, State Budgetary Institution of Healthcare of the Republic of Tyva Infectious Diseases Hospital, Russia
12:15-12:30	O7.2 Development of bat stem cell lines by somatic reprogramming to study bat-derived highly pathogenic viruses B. Pain, INSERM, France	O8.2 Positive impact of HBV vaccination in Lao PDR: Hepatitis B seroprevalence in adolescents L. Hefele, Luxembourg Institute of Health, Luxembourg
12:30-12:45	O7.3 A phase I trial of a chikungunya vaccine: fast induction of immune responses and safety upon a single dose of an unadjuvanted chimpanzee adenoviral vector A. Reyes-Sandoval, University of Oxford, UK	O8.3 Hepatitis B vaccination policy in healthcare workers in view of WHO's viral hepatitis elimination strategy A. De Schryver, University of Antwerpen, Belgium
12:45-13:00	O7.4 Synthetic Nucleic Acid Antibody Prophylaxis + DNA Vaccine Confers Rapid And Durable Protective Immunity Against Zika Virus K. Muthumani, Wistar University, USA	O8.4 A yellow fever vaccine virus-based therapeutic hepatitis B vaccine candidate inducing vigorous cytotoxic T cell responses R. Boudewijns, Rega Institute, KU Leuven, Belgium
13:00-14:00	Lunch <i>Room: Galaxy</i>	
	BREAKOUT SESSION 9 Preclinical and early clinical vaccine studies including TB Vaccines <i>Chairs: Kiat Ruxrungham and Helen Fletcher</i> <i>Room: Moon</i>	BREAKOUT SESSION 10 Novel vaccine delivery methods <i>Chairs: Danny Altmann and Tanapat Palaga</i> <i>Room: Lunar</i>

14:00-14:30	INV09 What's new in TB vaccine development Helen Fletcher , <i>London School of Hygiene and Trop Medicine, UK</i>	INV10 Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology Mark Orr , <i>Infectious Disease Research Institute, USA</i>
14.30-14.45	O9.1 - A novel therapeutic vaccine against multi-drug resistant tuberculosis in the preclinical study and phase 1 clinical trial M. Okada , <i>National Hospital Organization Kinki-Chuo Chest Medical Center, Japan</i>	O10.1 Mucosal delivery of a nanofiber booster vaccine for tuberculosis enhances generation of lung resident memory T cells J. Endsley , <i>UTMB, USA</i>
14:45-15:00	O9.2 - A vaccine targeting HIV maturation protects cynomolgus monkeys against vaginal SIVmac251 acquisition M. Luo , <i>National Microbiology Lab, Canada</i>	O10.2 Vaccination with 1/6th standard dose of a split inactivated influenza vaccine using the Nanopatch™ induces comparable immune responses to conventional full-dose intramuscular injection; results from a phase I randomized controlled clinical trial A. Forster , <i>Vaxxas, Australia</i>
15:00-15:15	O9.3 Efficacy of BCG in tuberculosis positive goat herds: Three-year follow-up C. Arrieta <i>IRTA, Spain</i>	O10.3 Needle Adapters and Needle-free Injectors for Intradermal Administration of Fractional Dose of Inactivated Poliovirus Vaccine: Pilot Polio Eradication Campaigns in Pakistan O. Mach , <i>WHO, Switzerland</i>
15:15-15:30	O9.4 Comparison of protective efficacies against primary and secondary TB infections conferred by BCG prime-boost strategy X-L Fan , <i>Huazhong University of Science and Technology, China</i>	
15:30--17:00	Refreshment break and Poster Session 2 <i>Room: Galaxy</i>	
17:00-18:30	BREAKOUT SESSION 11 - Roundtable Discussion- Vaccines and AMR– Policy and Funding Moderator: Greg Poland, <i>Editor in Chief, Vaccine and Mayo Clinic, USA</i> Panelists Helena Maltezou , <i>Hellenic Center for Disease Control and Prevention, Athens, Greece</i> Ivan Hung , <i>Hong Kong University, Hong Kong</i> Julia Spencer , <i>Associate Vice President Global Vaccines Public Policy, Partnerships, and Government Affairs, MSD, USA</i> <i>Room: Moon</i>	
19:30-22:00	Conference Dinner (ticketed)	
Wednesday 18 September 2019		
08:00-09:00	Researcher Academy on Campus – ECR Session Fundamentals of Publishing <i>Room: Moon/Lunar</i>	Researcher Academy on Campus -Mid Career Session Ensuring Visibility <i>Room: Galaxy 2</i>
09:00-11:00	PLENARY SESSION 3 Vaccines and the microbiome <i>Chairs: Galit Alter and Stitaya Sirisinha</i> <i>Room: Moon/Lunar</i>	
09:00-09.40	KEY06 The role of the microbiome in host interactions and vaccine responses Nichole Klatt , <i>University of Miami, USA</i>	
09.40-10.20	KEY07 Mucosal immunity in therapeutic and prophylactic vaccine trials Alexandra Schuetz , <i>AFRIMS, USA</i>	
10:20-11:00	KEY08 Translating the intestinal microbiome for oral vaccine performance Vanessa Harris , <i>Amsterdam UMC, University of Amsterdam, Netherlands</i>	
11:00-11:30	Refreshment break <i>Room: Galaxy</i>	

11:30-13:00	BREAKOUT SESSION 12 Late Breaker Session <i>Chairs: Florian Krammer and Surasakdi Wongratanacheewin</i> <i>Room: Moon</i>	BREAKOUT SESSION 13 A New Era in Vaccinology <i>Chairs: Galit Alter and Sathit Pichyangkul</i> <i>Room: Lunar</i>
11:30-12:00	INV11 The impact of pre-existing dengue immunity on Zika virus-induced damage during pregnancy Jean Lim , <i>Icahn School of Medicine at Mount Sinai, USA</i>	INV12 mRNA Vaccines — A New Era in Vaccinology Drew Weissman , <i>University of Pennsylvania, USA</i>
12:00-12:15	O11.1 Gastropodan hemocyanins - bio-adjuvants for viral, bacterial and tumor antigens A. Tchorbanov ^{1,2} , ¹ <i>Institute of Microbiology, Bulgarian Academy of Sciences, Bulgaria,</i> ² <i>National Institute of Immunology, Bulgaria</i>	O12.1 Epitope mapping of <i>Clostridioides difficile</i> flagellar proteins A. Razim Hirszfeld <i>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland</i>
12:15-12:30	O11.2 NS1-based DNA vaccination via in vivo electroporation is capable of conferring mouse protective immunity against ZIKV challenge. B.Y. Huang , <i>National Institute for Viral Disease Control and Prevention, China CDC, China</i>	O12.2 Enhancing Chikungunya Virus Immunity By Improved Vaccination K. Muthumani , <i>Wistar University, USA</i>
12:30-12:45	O11.3 Insertion-responsive microneedles for rapid intradermal delivery of influenza vaccine W. Na , <i>Chonnam National University, Republic of Korea</i>	O12.3 Preclinical generation and evaluation of an RH5.2-VLP vaccine for blood-stage malaria L. King , <i>University of Oxford, UK</i>
12:45-13:00	O11.4 Novel adenoviral vector platform for developing a universal influenza vaccine S. Mittal , <i>Purdue University, USA</i>	O12.4 Zika lineage-transcending protection by viral-vectored vaccines expressing structural antigens: Towards clinical trials A. Reyes-Sandoval <i>University of Oxford, UK</i>
13:00-13:30	Closing Session <i>Greg Poland and Kiat Ruxrungham</i> <i>Room: Moon</i>	
13:45-14:00	Spotlight on Asia session Introduction <i>Chairs: Ken Ishii, Sapna P. Sadarangani, and Kiat Ruxrungham</i> <i>Room: Moon</i>	
Session 1	Vaccine Immunology and Adjuvant:	
14:00-14:25	SA1 Innovation of vaccine adjuvant and new modality in Asia Ken Ishii , <i>University of Tokyo, Japan</i>	
14:25-14:55	SA2 Leptospirosis Vaccine Kanitha Patarakul , <i>Chula Vaccine Research Center, Chulalongkorn University, Thailand</i>	
Session 2	Primate research in vaccine development- perspectives from Japan and Thailand	
14:55-15:20	SA3 Essential role of primate research in vaccine development in Japan Yasuhiro Yasutomi , <i>National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan</i>	
15:20-15:45	SA4 Primate research for vaccine development in Thailand Suchinda Malaivijitnond , <i>National Primate Research Center, Chulalongkorn University, Thailand</i>	
Session 3	Bench and translational research	
15:45-16:10	SA5 Genetic mechanism of attenuation of the dengue vaccine strain PDK53 Dorothy Ng , <i>Singapore General Hospital, Singapore</i>	
16:10-16:35	SA6 Dengue prime/boost vaccine efficacy in non-human primate model Chutitorn Ketloy , <i>Chula Vaccine Research Center, Chulalongkorn University, Thailand</i>	
Session 4	Public health and vaccines	
16:35-17:00	SA7 Public health response to Measles resurgence- Singapore perspective Sapna P. Sadarangani , <i>NCID, Singapore</i>	
17:00-17:10	Closing remarks <i>Chairs: Ken Ishii, Sapna P. Sadarangani, and Kiat Ruxrungham</i>	
17:10-17:30	Networking and Refreshments	